Metformin reverts the mesenchymal and epithelial-to-mesenchymal transition (EMT) traits in intrahepatic CCA by activating AMPK-FOXO3-related pathways suggesting it might have therapeutic implications [20]. Here, FOXO3 is linked to cholangiocarcinoma.